ReviewNigerian medical journal : journal of the Nigeria Medical Association
Severe Mpox and Uncontrolled HIV Co-Infection in Lagos, Nigeria - A Case Report.
Review in Nigerian medical journal : journal of the Nigeria Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mpox, a re-emerging orthopoxvirus infection, shares clinical similarities with smallpox but is typically less severe. However, immunosuppressed individuals, including those with uncontrolled HIV infection, are at risk for severe and atypical clinical presentations of mpox. We report the case of a 40-year-old Nigerian man living with HIV who was non-adherent to antiretroviral therapy (ART) and presented with extensive vesiculopustular eruptions that evolved into vegetative, ulcerated plaques accompanied by fever, lymphadenopathy, and significant weight loss. Laboratory evaluation showed profound immunosuppression (CD4 <20 cells/μL), and polymerase chain reaction (PCR) testing for mpox was positive. He required 14 weeks of inpatient care, including supportive therapy, broad-spectrum antimicrobials, and intensive wound management. Mpox-specific antiviral therapies were unavailable. Although he achieved clinical recovery, he developed post-inflammatory alopecia, dyspigmentation, and significant psychological distress. This case highlights the risk of severe and prolonged mpox in people living with advanced HIV, the importance of early recognition and microbiological confirmation via PCR, and the need for multidisciplinary supportive care, including infection control, wound and skin management, ART optimisation, and mental-health support. Mpox-specific antivirals should also be made more accessible for patients with severe disease.
Indexed as
Identifiers
42471895PMC13379838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.